Featured Research

from universities, journals, and other organizations

Promising Indiana University Lung Cancer Trial Enters New Phase

Date:
January 15, 2002
Source:
Indiana University
Summary:
The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results. The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results.

The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The procedure uses a 3-D computer generated grid system to more precisely map the location where therapy is directed. The patient is positioned in a specially fitted, lightweight body frame that limits mobility to ensure the precision of photon beams aimed at the tumor. "One advantage of the combined technology is that the risk of damaging healthy tissue despite such potent doses of radiation is reduced in comparison to conventional radiation."

"The results of the first phase were very encouraging and somewhat surprising," says Robert D. Timmerman, M.D., assistant professor of radiation oncology and the trial's principal investigator at the Indiana University Cancer Center. "We thought patients only would be able to tolerate lower doses since frail patients typically can't tolerate such rigorous treatment. To our surprise, we were able to increase dose levels without prohibitive toxicity."

This latest phase seeks to enroll 35 patients with early stage, non-small cell lung cancer whose tumors have not spread to lymph nodes or beyond and who have health conditions such as emphysema, severe heart disease, diabetes or a history of strokes, therefore making them poor candidates for surgery.

"Using a potent dose with assurance of reasonable safety to patients, we now want to measure the rate of controlling lung cancer and measure the patient's overall disease-free survival," Dr. Timmerman says.

Early stage lung cancer traditionally is treated with surgery, conventional radiation, or both. There is a 60 percent to 70 percent cure rate for early stage lung cancer in patients undergoing surgery, and a 20 percent to 30 percent cure rate for those treated with conventional radiation, which usually involves up to six weeks of daily radiation treatments.

In contrast, Phase 2 of this IU lung cancer trial delivers the entire treatment in three visits.

"We're optimistic this new therapy will bridge this large disparity giving patients a better chance of survival and a cure," notes Dr. Timmerman.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. ScienceDaily, 15 January 2002. <www.sciencedaily.com/releases/2002/01/020115074910.htm>.
Indiana University. (2002, January 15). Promising Indiana University Lung Cancer Trial Enters New Phase. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2002/01/020115074910.htm
Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. www.sciencedaily.com/releases/2002/01/020115074910.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins